Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | December 15, 2016 | December 19, 2016 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | January 25, 2019 | January 29, 2019 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director | June 30, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date December 15, 2016 · Filed December 19, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2026-12-15 | Direct | 41,500 |
Reported balance
After 2016-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-15 · Grant · Acquired 41,500 · Balance 41,500 F1: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.
PALVELLA THERAPEUTICS, INC.
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2029-01-25 | Direct | 20,000 |
Reported balance
After 2019-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date.
Whitehawk Therapeutics, Inc.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,485 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 12,334 · Balance 24,485 F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 2, 2021 21:38 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantCommon Stock | 12,334 | $1.52 | $18,747.68 |
DisclosureSEC source: 0000899243-21-027290 · doc4.xml · nonDerivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,485 F1 · shares: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. F1 · price: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021. Read SEC document |
| March 31, 2021 Filed Apr 3, 2021 00:30 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantCommon Stock | 12,151 | $1.54 | $18,748.99 |
DisclosureSEC source: 0000899243-21-014672 · doc4.xml · nonDerivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,151 F1 · shares: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended March 31, 2021. F1 · price: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended March 31, 2021. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:42 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 52,144 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000899243-20-017774 · doc4.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,144 Underlying: Common Stock · 52,144 shares Expires 2030-06-24 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 21:24 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-19-017437 · doc4.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2029-06-18 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:42 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-19-000578 · primarydocument.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 22:04 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017749 · doc4.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-06-20 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 16:39 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001562180-18-000480 · primarydocument.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018. Read SEC document |
| January 25, 2017 Filed Jan 30, 2017 19:02 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-17-002202 · doc4.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2017. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 41,500 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001179022-16-000131 · edgar.xml · derivative · entry 1 Prelack Steven · CIK 0001302315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common stock · 41,500 shares Expires 2026-12-15 F1 · derivative.exercise_date: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.